| | |||||
| lung cancer | |||||
| 新闻 | |||||
| Olympus Launches New EBUS-TBNA Needle for Lung Cancer Staging and Diagnosis EBUS-TBNA, a procedure used in the diagnosis and staging of lung cancer, allows physicians to visualize diseased tissue, lymph nodes or lesions ...
| |||||
| Pulmonary toxicity of systemic lung cancer therapy Lung cancer is the leading cause of cancer-related deaths worldwide. As new therapies are developed, it is important to understand the pulmonary ...
| |||||
| Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for ... OBJECTIVES: To determine the rate of second primary lung cancer (SPLC) and describe the clinical characteristics and radiological findings in ...
| |||||
| Small cell lung cancer market size is expected to increase at a CAGR of 15.2% during the study ... Small cell lung cancer (SCLC) or Small cell lung carcinoma is an aggressive and most malignant form of tumor, characterized by the uncontrolled, rapid ...
| |||||
| Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients ... METHODS: The status of 10 targeted genes was evaluated by next-generation sequencing (NGS) in 884 non-small cell lung cancer (NSCLC) patients.
| |||||
| Opening and closing the doors of the lockdown in Italy without forgetting lung cancer patients However, patient should not be placed at an increased risk of dying of lung cancer just to avoid COVID-19. Attention must be paid to all types of ...
| |||||
| Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration ... ... chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer.
| |||||
| Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show" Genprex's lead drug candidate, GPX-001, for non-small cell lung cancer; How the Company is forging ahead during the COVID-19 pandemic; Company ...
| |||||
| Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients ... Cancer Immunol Immunother. ... In multivariable analysis, age ≥ 65 years, lung cancer diagnosis, and ICS use remained statistically associated with ...
| |||||
| 查看更多结果 | 修改此快讯 | |||||
| 您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
| 发送反馈 |
No comments:
Post a Comment